Skip to main content
. Author manuscript; available in PMC: 2017 Aug 28.
Published in final edited form as: Clin Cancer Res. 2009 Sep 8;15(18):5794–5802. doi: 10.1158/1078-0432.CCR-09-0911

Figure 3. SIM2 harbors HLA-A2.1-restricted immunogenic epitopes.

Figure 3

A. The binding to and rate of dissociation of peptides from HLA-A2.1 was determined by monitoring the decrease in HLA-A2.1 expression over time after incubation with binder peptides. B. Immunization of A2.1 transgenic HHD mice with the 9 binding peptides revealed 5 immunogenic SIM2 peptides as demonstrated by an IFN-γ ELISPOT assay. ** P<.01; *** P<.001.